Drug Profile
Phenylacetate
Latest Information Update: 18 Nov 2003
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Phenylacetates
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glioma
Most Recent Events
- 18 Nov 2003 Discontinued - Phase-II for Glioma in USA (IV)
- 28 Apr 1999 Phase-II clinical trials for Glioma in USA (IV)